ADAG
AdageneADAG
ADAG
About: Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Employees: 138
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
15% more funds holding
Funds holding: 13 [Q3] → 15 (+2) [Q4]
1.3% less ownership
Funds ownership: 20.21% [Q3] → 18.92% (-1.3%) [Q4]
20% less capital invested
Capital invested by funds: $25.3M [Q3] → $20.3M (-$5.02M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
463%
upside
Avg. target
$8
463%
upside
High target
$8
463%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Arthur He 9% 1-year accuracy 3 / 33 met price target | 463%upside $8 | Buy Reiterated | 3 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 days ago
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.
Neutral
GlobeNewsWire
1 month ago
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses
Neutral
GlobeNewsWire
1 month ago
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.
Neutral
GlobeNewsWire
1 month ago
Adagene to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida.
Neutral
GlobeNewsWire
1 month ago
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
- Trial to begin enrolling in April; expected primary completion in mid-2027 - - Primary study endpoint of rate of major pathological response - SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced an investigator initiated (IIT) Phase 2 neoadjuvant trial of ADG126 for patients with stage II or stage III colorectal cancer. The new study (NCT06846268), led by primary investigator Dr. Yong Wei Peng, Senior Consultant at the Department of Haematology-Oncology, National University Cancer Institute, Singapore, is expected to begin patient enrollment in April 2025.
Neutral
GlobeNewsWire
2 months ago
CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
Neutral
GlobeNewsWire
3 months ago
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA on Saturday, January 25, 2025.
Positive
Zacks Investment Research
3 months ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Negative
Zacks Investment Research
4 months ago
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
5 months ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Charts implemented using Lightweight Charts™